Narsoplimab (OMS721)
HSCT-Associated Thrombotic Microangiopathy (HSCT-TMA)
Key Facts
About Omeros Corporation
Omeros Corporation is a Seattle-based biopharma company with a 30-year history focused on discovering and commercializing first-in-class therapeutics for large-market and orphan indications. The company achieved a pivotal transition to commercial operations with the 2014 FDA approval of OMIDRIA® for cataract surgery and is now advancing a deep pipeline anchored by its novel lectin pathway complement inhibitor, narsoplimab, targeting severe conditions like hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Omeros's strategy combines revenue generation from its commercial asset with targeted R&D investments in its proprietary GPCR and immunology platforms to address high-value, underserved medical markets.
View full company profileAbout Omeros Corporation
Omeros Corporation is a Seattle-based biopharma company with a 30-year history focused on discovering and commercializing first-in-class therapeutics for large-market and orphan indications. The company achieved a pivotal transition to commercial operations with the 2014 FDA approval of OMIDRIA® for cataract surgery and is now advancing a deep pipeline anchored by its novel lectin pathway complement inhibitor, narsoplimab, targeting severe conditions like hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Omeros's strategy combines revenue generation from its commercial asset with targeted R&D investments in its proprietary GPCR and immunology platforms to address high-value, underserved medical markets.
View full company profileAbout Omeros Corporation
Omeros Corporation is a Seattle-based biopharma company with a 30-year history focused on discovering and commercializing first-in-class therapeutics for large-market and orphan indications. The company achieved a pivotal transition to commercial operations with the 2014 FDA approval of OMIDRIA® for cataract surgery and is now advancing a deep pipeline anchored by its novel lectin pathway complement inhibitor, narsoplimab, targeting severe conditions like hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Omeros's strategy combines revenue generation from its commercial asset with targeted R&D investments in its proprietary GPCR and immunology platforms to address high-value, underserved medical markets.
View full company profile